Yang et al. (12) found that the overexpression of BAG2 in triple-negative breast cancer was closely associated with poor clinical results, and the unique role of BAG2 was confirmed as an enzyme of cancer-promoting or anticancer genes. Here, BAG2 is linked to triple-negative breast carcinoma.